Cytek Biosciences

Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Cytek Biosciences reports mixed Q1 results, eyes strategic growth

Cytek Biosciences saw mixed Q1 performance with revenue growth from acquisitions but organic revenue decline.
Strategic partnerships and product launches are strengthening Cytek's position in the market.
Challenges in revenue growth and increased expenses highlight the need for operational efficiency.
Despite financial setbacks, Cytek remains optimistic about future growth opportunities and market leadership.

Cytek Biosciences reports strong Q2 earnings, eyes growth opportunities

Cytek Biosciences delivered a robust performance in Q2 2023, marked by strong revenue growth and operational efficiency despite increased expenses.
The company's strategic focus on driving growth through acquisitions, technology advancements, and market opportunities bodes well for future expansion.
While challenges in managing expenses persist, Cytek's solid financial position and confidence in addressing market needs position it for sustained growth.
With a clear roadmap for growth and a talented team, Cytek remains poised to capitalize on opportunities and enhance shareholder value.

Cytek Biosciences reports solid Q3 growth and eyes global expansion

Cytek Biosciences delivered strong Q3 results with revenue growth and strategic focus on key pillars.
Despite challenges in sales cycles and order delays, the company remains innovative and responsive in the market.
Opportunities in new product launches, bioinformatics, and clinical markets provide avenues for future growth.
Cytek's performance reflects resilience amidst industry challenges and a commitment to driving innovation and expansion.

Cytek Biosciences reports robust Q4 earnings, eyes growth opportunities

Cytek Biosciences delivered strong financial results in Q4 2023, driven by revenue growth and operational efficiency, with a focus on profitability and innovation.
The company faces challenges in managing expenses, stabilizing revenue in key markets, and balancing new product contributions with cost control measures.
Opportunities lie in capitalizing on revenue outlook, expanding in the biotech segment, leveraging regional growth, and diversifying revenue streams.
Strategic planning and execution will be crucial for Cytek Biosciences to navigate challenges and maximize opportunities for sustainable growth and market leadership.

Cytek Biosciences reports strong Q1 growth amidst global market expansion

Cytek Biosciences' Q1 2024 performance reflects solid revenue growth and market expansion efforts.
While facing challenges in certain regions, the company is leveraging opportunities in product innovation and global demand.
Maintaining financial discipline and focusing on operational efficiency will be key to achieving profitability and sustained growth.

Cytek Biosciences reports Q2 revenue growth, eyes global expansion

Cytek Biosciences showed mixed performance in Q2 2024 with revenue growth in EMEA and APAC but a decline in the U.S., particularly in academic and government sectors.
The company's focus on key growth pillars and new capabilities like the ESP module, along with strategic initiatives like Cytek Cloud, positions it for future growth.
While facing challenges in the U.S. market, Cytek Biosciences aims to drive sustainable growth and profitability through cost control and revenue enhancement strategies.

Cytek Biosciences reports strong Q3 earnings, eyes global expansion

Cytek Biosciences demonstrated solid financial performance in Q3 2024, driven by revenue growth and effective expense management.
The company's strategic focus on key pillars and expanding user base positions it well for future success and market leadership.
While facing challenges in balancing investments and income, Cytek has opportunities to capitalize on global growth and market trends.

Cytek Biosciences reports solid 2024 performance amidst growth opportunities

Cytek Biosciences demonstrated strong financial performance in 2024, driven by service revenue growth and operational efficiency improvements. While facing challenges from external factors and a slight decline in Q4 revenue, the company's focus on innovation and cost control positions it well for future growth. Opportunities lie in expanding market presence, leveraging new technologies, and navigating regulatory changes to achieve revenue targets and sustain profitability.

Cytek Biosciences reports Q1 revenue decline but eyes global growth

Cytek Biosciences navigated challenges in instrument sales with strong growth in service revenue and international markets. Strategic investments and a focus on recurring revenue position Cytek for future growth and market resilience. Maintaining a balance between share repurchases, M&A opportunities, and revenue growth is crucial for Cytek's success. Despite market uncertainties, Cytek's global supply chain resilience and product pipeline investments offer promising opportunities.

Cytek Biosciences reports Q2 revenue decline but strong recurring growth

Cytek Biosciences faced revenue decline in Q2 2025 but saw strong recurring revenue growth. The company's focus on core areas and stock repurchase demonstrate strategic strength. Challenges include declining margins and losses, with opportunities in global market expansion.

Cytek Biosciences reports 2% revenue growth in Q3 2025

Cytek Biosciences delivered solid revenue growth in Q3 2025, driven by APAC and recurring revenue businesses Expansion of global footprint and introduction of new products like Aurora Evo Analyzer contributed to growth Challenges in stabilizing U.S. instruments market highlight the need for continued focus Opportunities lie in leveraging strong performance in APAC and expanding reagent revenue globally

Cytek Biosciences reports solid Q4 performance and targets growth in 2026

Cytek Biosciences delivered a strong performance in Q4 2025 and outlined strategic goals for 2026 to drive growth and innovation. While facing financial challenges, the company's focus on operational efficiency and revenue diversification positions it well for future success. Opportunities for growth lie in expanding market presence, advancing technology, and enhancing profitability through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.